VLGC Virologic (MM)

ViroLogic to Present at Lazard's 1st Annual Life Sciences Conference on November 30, 2004 SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced today that Bill Young, CEO and Chairman, is scheduled to present a corporate overview at Lazard's 1st Annual Life Sciences Conference on Tuesday, November 30, 2004 at 8:30 a.m. EST. This event will be held at the Mandarin Oriental Hotel (Grand Salon) in New York City. To access the live audio broadcast, or the subsequent archived recording, log on to http://www.virologic.com/ and go to the investor relations section. The archived version of the webcast will be available online for one month. About ViroLogic ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company's products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at http://www.virologic.com/ . Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the timing of pharmaceutical company clinical trials, risks related to our pending merger with ACLARA BioSciences, Inc. (ACLARA), including the risk that the closing conditions of the merger may not be satisfied and the merger may not be completed, and costs related to the proposed merger may adversely impact ViroLogic's financial performance, the risks that the Company's products may not perform, whether ViroLogic successfully introduces new products, risks related to the implementation of the Company's distribution agreement with a major national laboratory, whether others introduce competitive products, the risk that the Company's products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that gross margins may not increase as expected, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic's products or services, whether the Company will encounter problems or delays in automating its processes, whether intellectual property underlying the Company's PhenoSense(TM) technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of these and other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and the Joint Proxy/Prospectus related to the proposed merger with ACLARA, as well as other subsequent filings with the Securities and Exchange Commission. DATASOURCE: ViroLogic, Inc. CONTACT: Investor Relations, ViroLogic, Inc., +1-650-635-1100 Web site: http://www.virologic.com/

Copyright